MedTrace Logo

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

NCT04647357 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-11-30

No results posted yet for this study

Summary

SHR-1316 as Maintenance therapy for limited stage small cell lung cancer without progression after first line platinum based concurrent chemoradiotherapy

Conditions

  • Limited-stage Small Cell Lung Cancer, LS-SCLC

Interventions

DRUG

SHR-1316

Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-27
Primary Completion
2023-05-27
Completion
2023-12-27

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04647357 on ClinicalTrials.gov